0.7500USD-1.32%Mkt Cap: 27.51M USDP/E: —Last update: 2026-05-26
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Produ…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap27.51M USD
Enterprise Value26.41M USD
Revenue (TTM)3.81M USD
Gross Profit-1.09M USD
Net Income (TTM)-7.36M USD
Revenue/Share0.1110 USD
Last Price0.7500 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.31
PEG—
EV/EBITDA—
EV/Revenue6.94
P/S7.08
P/B21.76
EPS (TTM)-0.21
EPS (Forward)-0.32
52W Range
0.650014% of range1.350
52W High1.350 USD
52W Low0.6500 USD
Profitability
Gross Margin-88.25%
Oper. Margin-172.13%
EBITDA Margin0.00%
Profit Margin-597.63%
ROE-597.58%
ROA-74.05%
Growth
Revenue Growth182.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.70M USD
CapEx (TTM)—
FCF Margin-107.68%
FCF Yield-14.90%
Net Debt-554.89K USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity4.11
Current Ratio2.42
Quick Ratio2.08
Book Value/Sh0.0340 USD
Cash/Share0.1540 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)6.000 USD
Target Range5.000 USD – 7.000 USD
# Analysts2
Ownership
Shares Out.36.44M
Float27.37M
Insiders25.53%
Institutions14.96%
Short Interest
Short Ratio0.9d
Short % Float0.20%
Short % Out.0.15%
Shares Short55.97K
Short (prev mo.)130.01K
Technical
SMA 500.8038 (-6.7%)
SMA 2000.9106 (-17.6%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)76.03K
Avg Vol (10d)100.34K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—